Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2014

Open Access 01-09-2014 | Educational Series - Blue Series

Overview of a chemoresponse assay in ovarian cancer

Authors: E. C. Grendys Jr., J. V. Fiorica, J. W. Orr Jr., R. Holloway, D. Wang, C. Tian, J. K. Chan, T. J. Herzog

Published in: Clinical and Translational Oncology | Issue 9/2014

Login to get access

Abstract

The objective of this review is to summarize recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance assays (CSRAs), specifically as applied to epithelial ovarian cancer. A total of sixty-seven articles, identified through PubMed using the key words “in vitro chemoresponse assay,” “chemo sensitivity resistance assay,” “ATP,” “HDRA,” “EDR,” “MiCK,” and “ChemoFx,” were reviewed. Recent publications on marker validation, including relevant clinical trial designs, were also included. Recent CSRA research and clinical studies are outlined in this review. Published findings demonstrate benefits regarding patient outcome with respect to recent CSRAs. Specifically, analytical and clinical validations, as well as clinical utility and economic benefit, of the most common clinically used CSRA in the United States support its use to aid in making effective, individualized clinical treatment selections for patients with ovarian cancer.
Literature
1.
American Cancer Society. Cancer Facts and Figures 2014. Atlanta: American Cancer Society; 2014.
2.
du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320–9.PubMedCrossRef
3.
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98(15):1036–45.PubMedCrossRef
4.
du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol. 2006;24(7):1127–35.PubMedCrossRef
5.
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25.PubMedCentralPubMedCrossRef
6.
Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.PubMedCrossRef
7.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.CrossRef
8.
Thigpen T. A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol. 2012;55:114–30.PubMedCrossRef
9.
Galic V, Coleman RL, Herzog TJ. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets. 2013;13(6):698–707.PubMedCrossRef
10.
Abada P, Howell SB. Regulation of Cisplatin Cytotoxicity by Cu Influx Transporters. Metal-Based Drugs. 2010;2010:317581.
11.
Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res. 2003;9:5299–305.PubMed
12.
Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9.PubMedCrossRef
13.
Helleman J, Van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer (Internet) BioMed Central. 2006;6(1):201.
14.
Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H, et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch. 2005;447(3):626–33.PubMedCrossRef
15.
Huzil JT, Chen K, Kurgan L, Tuszynski JA. The roles of β-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inf. 2007;3:159–81.
16.
Jacobs IJ, Kohler MF, Wiseman R, Marks JR, Whitaker R, Kerns BA, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation. J Natl Cancer Inst. 1992;84:1793–8.PubMedCrossRef
17.
18.
Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10(13):4420–6.PubMedCrossRef
19.
Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001;61(5):1862–8.PubMed
20.
Zhou J, O’Brate A, Zelnak A, Giannakakou P. Survivin deregulation in tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res. 2004;64:8708–14.PubMedCrossRef
21.
Tumbarello DA, Temple J, Brenton JD. β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Mol Cancer. 2012;11:36.PubMedCentralPubMedCrossRef
22.
Steffensen KD, Smoter M, Waldstrøm M, Grala B, Bodnar L, Stec R, et al. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression. Int J Oncol. 2014;. doi:10.​3892/​ijo.​2014.​2311.PubMed
23.
Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.CrossRef
24.
Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88(20):1456–66.PubMedCrossRef
25.
Samson D, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol. 2004;22(17):1–13.CrossRef
26.
Black M, Speer F. Effects of cancer chemotherapeutic agents on dehydrogenase activity of human cancer tissue in vitro. Am J Clin Pathol. 1953;23:218–27.PubMed
27.
Cree IA. Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol. 2009;21(1):39–43.PubMedCrossRef
28.
Salom E, Penalver M, Homesley H, Burrell M, Garrett A, Presant CA, et al. Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. J Transl Med. 2012;10:162.PubMedCentralPubMedCrossRef
29.
Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 1978;298:1321–7.PubMedCrossRef
30.
Selby PJ, Raghavan D. Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients. J Clin Pathol. 1981;34(5):455–63.PubMedCentralPubMedCrossRef
31.
Cree IA, Kurbacher CM. ATP-based tumor chemosensitivity testing: assisting new agent development. Anticancer Drugs. 1999;10(5):431–5.PubMedCrossRef
32.
Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med. 2005;110:101–20.PubMed
33.
Jung P, Kim DY, Kim MB, Lee SW, Kim JH, Kim YM, et al. Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res. 2013;33:1029–34.PubMed
34.
Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S, TCA Ovarian Cancer Trial Group. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs. 2007;18:1093–101.PubMedCrossRef
35.
Gao YT, Wu LY, Zhang W, Zhao D, Li N, Tian HM, et al. A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 2013;48(5):358–63.PubMed
36.
Sharma S, Neale MH, Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer. 2003;3:19.PubMedCentralPubMedCrossRef
37.
Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D, et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res. 2008;28:949–56.PubMed
38.
Ness RB, Wisniewski SR, Eng H, Christopherson W. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer Res. 2002;22(2B):1145–9.PubMed
39.
Bosserman LD, Rajurkar SP, Rogers K, Davidson DC, Chernick M, Hallquist A, et al. Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival. Cancer. 2012;118(19):4877–83.PubMedCrossRef
40.
Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, et al. The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Cancer Res. 2012;72(16):3901–5.PubMedCrossRef
41.
Ballard KS, Homesley HD, Hodson C, Presant CA, Rutledge J, Hallquist A, et al. Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. J Gynecol Oncol. 2010;21(1):45–9.PubMedCentralPubMedCrossRef
42.
Strickland SA, Raptis A, Hallquist A, Rutledge J, Chernick M, Perree M, et al. Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. Leuk Lymphoma. 2013;54(3):528–34.PubMedCrossRef
43.
Brower SL, Fensterer JE, Bush JE. The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol. 2008;414:57–78.PubMed
44.
Heinzman JH, Rice SD, Corkan LA. Robotic liquid handlers and semi-automated cell quantification systems increase consistency and reproducibility in high-throughput, cell based assay. J Lab Autom. 2010;15:7–15.CrossRef
45.
Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol. 2010;203(68):e1–6.PubMed
46.
Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer. 2006;16:194–201.PubMedCrossRef
47.
Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea R, Backner A, et al. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res. 2008;28(3B):1733–40.PubMed
48.
49.
Rutherford T, Orr J Jr, Grendys E Jr, Edwards R, Krivak TC, Holloway R, et al. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol. 2013;131(2):362–7.PubMedCrossRef
50.
51.
Polley MC, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst. 2013;105(22):1677–83.PubMedCrossRef
52.
53.
Mark DH, Ratko TA. Blue cross and blue shield technology evaluation center special report: multiple molecular testing of cancers to identify targeted therapies. 2013;28(1):1–16.
54.
Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, et al. American Society of Clinical Oncology Clinical Practice-Guideline Update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011;29(24):3328–30.PubMedCrossRef
55.
Bluecross blueShield association. Chemotherapy sensitivity and resistance assays. Chicago: BlueCross blueshield association (BCBS). TEC assessment 2002;17(12):1–39.
56.
Deverka P, Messner D, Dutta T. Evaluation of clinical validity and clinical utility of actionable molecular diagnostic tests in adult oncology. Center for Medical Technology Policy (CMTP) Effective Guidance Document. 2013.
57.
Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res. 2014;20:1428.PubMedCrossRef
58.
Khoury MJ, Berg A, Coates R, Evans J, Teutsch SM, Bradley LA. The evidence dilemma in genomic medicine. 2008;27(6):1600–11.
59.
Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, et al. The Scientific Foundation for personal genomics: recommendations from National Institutes of Health-Centers for Disease Control and Prevention Multidisciplinary Workshop. Genet Med. 2009;11(8):559–67.PubMedCentralPubMedCrossRef
60.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genetics Med. 2009;11:66–73.CrossRef
61.
Havrilesky LJ, Krivak TC, Mucenski JW, Myers ER. Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. Am J Obstet Gynecol. 2010;203(2):160.e1–7.
62.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.PubMedCrossRef
63.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.PubMedCrossRef
64.
Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, et al. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol. 2013;130(1):19–24.PubMedCrossRef
65.
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107–14.PubMedCrossRef
66.
Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176–82.PubMedCrossRef
67.
Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004;90(11):2112–7.PubMedCentralPubMed
Metadata
Title
Overview of a chemoresponse assay in ovarian cancer
Authors
E. C. Grendys Jr.
J. V. Fiorica
J. W. Orr Jr.
R. Holloway
D. Wang
C. Tian
J. K. Chan
T. J. Herzog
Publication date
01-09-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 9/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1192-8

Other articles of this Issue 9/2014

Clinical and Translational Oncology 9/2014 Go to the issue

Research Article

Nin one binding protein expression as a prognostic marker in prostate carcinoma

Research Article

Iron deficiency in patients with solid tumours: prevalence and management in clinical practice

Research Article

Intraoperative radiotherapy-containing multidisciplinary management of trunk-wall soft-tissue sarcomas

Research Article

Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model

Research Article

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer

Research Article

Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits